As of January 22, 2025, enGene (ENGN) has a market cap of $0.35 billion USD. According to our data, enGene is ranked No.6500 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.35 B |
4.51%
|
Dec 31, 2024 | $0.34 B |
-27.95%
|
Dec 29, 2023 | $0.47 B |
-10.65%
|
Dec 30, 2022 | $0.53 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.39 B |
-0.000 M
|
USA
|
Voyager Therapeutics
VYGR
|
$0.30 B |
-0.000 M
|
USA
|
Adverum Biotechnologies
ADVM
|
$92.99 M |
-0.000 M
|
USA
|
uniQure
QURE
|
$0.82 B |
0.000 M
|
Netherlands
|
Generation Bio
GBIO
|
$63.83 M |
-0.000 M
|
USA
|
MeiraGTx
MGTX
|
$0.47 B |
-0.000 M
|
USA
|
Market Cap | = | ENGN Stock Price | * | ENGN Shares Outstanding |
= | $6.95 | * | 50.98 M | |
= | $0.35 B |